Friday Pop Quiz 7/18/2025
A 45-year-old man presents to the office with weakness and the lesions on his hand pictured. His symptoms have been progressively worsening over the last 5 months. He works as a nurse and has had difficulty walking up the stairs and lifting patients. He has a history of frontal migraines for which he occasionally takes ibuprofen. He takes a cholesterol lowering medication and is otherwise heal …
A 45-year-old man presents to the office with weakness and the lesions on his hand pictured. His symptoms have been progressively worsening over the last 5 months. He works as a nurse and has had difficulty walking up the stairs and lifting patients. He has a history of frontal migraines for which he occasionally takes ibuprofen. He takes a cholesterol lowering medication and is otherwise heal … 
June and July mark a major milestone—you’re wrapping up intern year and are finally starting dermatology residency. You’ve survived night shifts, rapid responses, and figuring out how to juggle clinical demands like a pro. Just when you felt like you were getting the hang of things… you’re resetting the clock and diving headfirst into a specialty that sometimes feels like an entirely dif … 
The July 2025 issue of the Journal of Drugs in Dermatology brings together another outstanding selection of articles, offering cutting-edge insights and real-world strategies across a diverse range of dermatology topics. This month’s editor’s highlights spotlight innovative approaches to photoprotection in melasma and photodamage, emerging non-pharmaceutical solutions for fem … 
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory … 
A 70-year-old woman with biopsy-confirmed bullous pemphigoid presents with new-onset confusion, hypotension, and leukocytosis two weeks after starting systemic prednisone 60 mg daily. She also reports tremors and blood glucose of 320 mg/dL. What is the next best step in management?
A. Taper corticosteroids and begin doxycycline and …